Aurobindo Pharma is currently trading at Rs. 622.95, up by 6.65 points or 1.08% from its previous closing of Rs. 616.30 on the BSE.
The scrip opened at Rs. 621.00 and has touched a high and low of Rs. 625.50 and Rs. 615.40 respectively. So far 16667 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.
Last one week high and low of the scrip stood at Rs. 655.00 and Rs. 603.30 respectively. The current market cap of the company is Rs. 36420.51 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.
Aurobindo Pharma is eyeing to invest up to $200 million on Capex and over five percent of sale value on Research and Development (R&D) during the current financial year. The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities.
The company had spent $225 million on capex last year and R&D expenditure was at Rs 872 crore or 4.5 percent of the revenues for the year.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.90 |
| Dr. Reddys Lab | 1237.60 |
| Cipla | 1237.10 |
| Zydus Lifesciences | 941.00 |
| Lupin | 2328.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: